HT
IMVT icon

Headlands Technologies’s Immunovant IMVT Stock Holding History

Headlands Technologies’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,212
Closed -$361K – 836
2025
Q4 		$361K Sell
14,212
-24,174
-63% -$539K 0.03% 477
2025
Q3 		$619K Buy
38,386
+38,322
+59,878% +$620K 0.05% 313
2025
Q2 		$1.02K Sell
64
-2,897
-98% -$43.8K ﹤0.01% 1126
2025
Q1 		$50.6K Buy
+2,961
New +$61.9K 0.01% 710
2024
Q3 		– Sell
-2,927
Closed -$77.3K – 1353
2024
Q2 		$77.3K Buy
+2,927
New +$83.3K 0.01% 695
2024
Q1 		– Sell
-636
Closed -$26.8K – 1393
2023
Q4 		$26.8K Buy
+636
New +$23.4K 0.01% 626

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Headlands Technologies's IMVT Position: Q1 2026 in Review

Headlands Technologies sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 14,212 shares — an estimated $361K sold.

Headlands Technologies first reported a position in IMVT in Q4 2023 and held it in 6 quarters. The position peaked at $619K in Q3 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Headlands Technologies reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 14,212 Immunovant shares in Q1 2026, an estimated $361K.
  • Headlands Technologies first reported a position in Immunovant in Q4 2023 and held it in 6 quarters.
  • Headlands Technologies's Immunovant position peaked at $619K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.